INTRODUCTION AND OBJECTIVES:
Evolving research suggests that up to 12% of metastatic prostate cancer (PC) cases are attributable to hereditary cancer risk. Targeted therapy may be suitable for some men with identified pathogenic variants (PVs) in specific genes. Recent updates to NCCN guidelines encourage germline genetic testing (GT) be considered in men with high or very high risk, regional, and metastatic PC. In response, our institution implemented clinical GT in this population of men with PC. This study evaluated GT results and clinical characteristics of men with PC who underwent genetic evaluation.
METHODS: Men with PC referred to genetic counseling and multi-gene GT by genitourinary (GU) clinicians from June 2016-June 2018 were included. Clinical characteristics and germline GT were analyzed.
RESULTS: Of 285 men referred by GU clinicians, 201 had evaluable GT results. One PV was excluded for suspicion of clonal hematopoiesis of indeterminate potential. Overall, 27 PVs were identified in 24 men (12.4%). Three men had 2 PVs identified (1.5%), of which at least one was in ATM or BRCA2. PVs were distributed amongst ATM (n[6, 3.0%), BRCA2 (n[7, 3.5%), MYH (n[4, 2.0%), HOXB13 (n[4, 2.0%), CHEK2 (n[1, 0.5%), NBN (n[1, 0.5%), PALB2 (n[1, 0.5%), and SDHA (n[1, 0.5%). Statistically, men with PVs showed no difference in grade group (Group 1-3: 10.1%, Group 4-5: 13.6%; p[.49) and were distributed across multiple NCCN risk groups. Family history of prostate cancer was also not statistically associated with genetic test results (PV: 54%, no PV: 37%; p[0.11).
CONCLUSIONS: Utilization of GT may lead to changes in therapeutic selection and changes in management to men with PC and their family members. PVs in ATM and BRCA2 align with previous research, and the identification of HOXB13 variants suggest its inclusion in multi-gene GT for men with PC. Collaboration with genetics professionals can facilitate risk assessment and appropriate GT for men with advanced PC.
Source of Funding: None

MP41-07 TRENDS IN COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG NEWLY DIAGNOSED PROSTATE CANCER PATIENTS
Kyle B Zuniga*, Shoujun Zhao, San Francisco, CA; Benjamin E. Cedars, Philadelphia, PA; Janet E. Cowan, Stacey A. Kenfield, Erin L. Van Blarigan, Jeanette M. Broering, Peter R. Carroll, June M. Chan, San Francisco, CA INTRODUCTION AND OBJECTIVES: Complementary and alternative medicine (CAM) use is common among prostate cancer (PCa) patients. The benefits and risks of the majority of CAM are inconclusive, and thus understanding trends in use is necessary to guide future research. Using the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), we sought to investigate the prevalence of CAM use among PCa patients and to explore trends in CAM use among newly diagnosed PCa patients.
METHODS: Between 1996 Between -2017 CaPSURE subjects completed questionnaires on use of over 50 CAM types. For prevalence, subjects were identified as users if they ever indicated CAM use. We then performed univariate analyses to examine associations between sociodemographic and clinical characteristics with CAM use using chi-squared tests. To observe trends in CAM use among newly diagnosed patients, we limited subject responses to questionnaires
